Top 5 US Stocks To Buy In April 2026

These 5 stocks are our top Pro Picks for this month, taken from S&P 500-listed companies that have garnered high InvestingPro health ratings (benchmarked against more than 100 financial factors and indicators from companies in the same sector), as well as from among those trading well under our proprietary fair value estimates (based on 5 overlaid investing models) and analyst assessments.

All of these names have earned InvestingPro health scores of well above 3.00 (Good, Great or Excellent), which for the last 7 years has indicated outperformance vs. the S&P 500. A score this high points to a mix of first-rate financials: excellent earnings, cash flow, and growth vs. peers in its sector.

Importantly, all of these stocks are also currently undervalued per InvestingPro’s fair value calculations and favored by Wall Street analysts polled by InvestingPro. They’re also sitting with a current potential upside of more than 20%. So if you’re eager to bulk up your portfolio, these overlooked powerhouse plays are all worth serious consideration.

• InvestingPro health score: Great
• InvestingPro average fair value: $39.35 / 42.6% upside
• Fair value confidence: Medium
• Industry: Healthcare / Pharmaceuticals

Harmony Biosciences Holdings, Inc. (HRMY) stands out as a compelling investment opportunity in the biopharmaceutical sector for April 2026. Specializing in innovative therapies for rare neurological disorders, Harmony has made significant strides, backed by a robust development pipeline and promising product lineup. As of the end of March 2025, Harmony Biosciences has a market capitalization of approximately $1.59 billion, demonstrating its robust position as a mid-cap firm in the competitive biotech domain.

The company currently does not pay a dividend, choosing instead to allocate its profits towards research and development efforts aimed at expanding its market offerings and driving sustained growth. Harmony’s P/E ratio is reported at 10.1, which is above industry norms in relation to its closest peers, but still holds potential for upside (analysts anticipate roughly a 42.6% potential upside) due to anticipated product launches and expanding market reach.

Harmony maintains a prudent approach to debt management, providing the flexibility needed to support its strategic expansions, including partnerships and potential new acquisitions in the sector. Investors should note that while the biotech industry can be volatile, Harmony’s focus on unique therapeutic areas provides it with a defensive edge.

Overall, Harmony Biosciences offers a promising opportunity for investors seeking exposure to the biotech field, particularly those interested in companies with strong growth trajectories and strategic initiatives aimed at addressing unmet medical needs.

• InvestingPro health score: Excellent
• InvestingPro average fair value: $97.95 / 25.4% upside
• Fair value confidence: High
• Industry: Consumer Staples / Food Products

Cal-Maine Foods Inc earns their second month our list as stock pick for April 2026. As of the latest quarter, the company boasts a market capitalization of around $3.72 billion, marking it as a notable player in the consumer staples (food). Cal-Maine Foods specializes the production, grading, packaging, marketing, and distribution of shell eggs, egg products, and prepared foods.

The company pays a quarterly dividend of (currently) 3.6%, providing investors with steady income alongside potential capital appreciation. With a P/E ratio of 3.2, Cal-Maine Foods appears relatively undervalued compared to industry peers, hinting at potential upside, especially if egg market production remains robust.

Cal-Maine Foods maintains a prudent debt strategy, evidenced by a debt-to-equity ratio of 0.0% (which is common for them), which supports its operational diligence. Investors considering this stock should be aware of the volatility resilience associated with staple products, highlighted by their current 1-Year Beta of just 0.25.

Overall, Cal-Maine Foods’ strategic positioning and disciplined financial management enhance its appeal. The company is well-positioned to benefit from favorable market conditions, making it a compelling choice for investors seeking exposure to a resilient sector with the potential for both income and growth.

• InvestingPro health score: Great
• InvestingPro average fair value: $2.16 / 43.2% upside
• Fair value confidence: Medium
• Industry: Healthcare / Pharmaceuticals

SNDL Inc (SNDL) presents a solid investment opportunity as we head into April 2026, especially for investors seeking opportunities in the pharmaceuticals sector. With a market capitalization of roughly $352.2 million as of the end of March, SNDL is a small player with significant potential upsides.

While SDNL doesn’t pay a shareholder dividend, this shows the business instead prioritizes strategic growth, reinvesting earnings to enhance shareholder value through a range of acquisitions and ventures. While the current P/E ratio is -30.9, the company is looking on track to be profitable this year with a high shareholder yield and strong liquid assets.

Speaking of risks, however, it’s important to note that SNDL operates in sectors characterized by regulatory volatility and competitive dynamics, which can lead to significant stock price fluctuations.

Despite these challenges, SNDL has managed its debt levels effectively, ensuring financial stability as it explores new markets and products. This disciplined approach to expansion, combined with potential new legislative changes favoring cannabis legalization, could catalyze growth and enhance shareholder value. Overall, SNDL Inc. presents a dynamic investment opportunity for those looking to leverage the evolving landscape of the cannabis and alcohol sectors.

• InvestingPro health score: Great
• InvestingPro average fair value: $126.20 / 25.3% upside
• Fair value confidence: High
• Industry: Marine Transportation

Danaos Corp (DAC) stands out as a noteworthy stock pick for April 2026, particularly for investors interested in the maritime shipping sector. As of the close of March, Danaos boasts a market capitalization of approximately $2.06 billion, positioning it as a significant player in the container shipping industry. The company has earned recognition for its expansive fleet and strategic partnerships, allowing it to capitalize on global trade dynamics.

Danaos offers an attractive dividend yield, currently at 3.2%, providing an added incentive for income-focused investors. The company maintains a P/E ratio of 4.2, suggesting that the stock is undervalued relative to its earnings, offering a promising upside of more than 25% for those looking to capitalize on market inefficiencies.

In terms of financial health, Danaos manages its debt prudently, with a focus on refinancing its liabilities to maintain operational flexibility and fund future growth. Investors should be conscious, however, of the inherent volatility in the shipping industry, driven by fluctuating freight rates and global economic conditions.

Overall, Danaos Corp presents a compelling investment opportunity, combining a strong dividend with growth potential in the dynamic shipping industry. Its ability to adapt to market changes and its strategic positioning in the global trade sector underscore its appeal to investors seeking both stability and growth prospects.

• InvestingPro health score: Good
• InvestingPro average fair value: $194.91 / 64.1% upside
• Fair value confidence: Medium
• Industry: Textiles, Apparel & Luxury Goods

For investors targeting the consumer discretionary sector, Lululemon Athletica (LULU) presents a compelling growth story. As a global leader in athletic apparel and lifestyle products, the company boasts a substantial market capitalization of approximately $13.73 billion (as of the end of March 2026). Its current Price-to-Earnings (P/E) ratio stands at 11.6, reflecting strong investor confidence in its future earnings potential and premium brand positioning, which was reinforced by solid performance in the last quarter.

Financially, Lululemon operates with a very strong balance sheet and minimal debt, allowing it to self-fund its aggressive expansion into new product categories and international markets. The company does not currently pay a dividend, instead prioritizing the reinvestment of profits to fuel this growth.

Analysts see a potential upside of just over 64% for the stock, driven by continued brand loyalty and successful market penetration. With a beta of 1.27, the stock exhibits a similar volatility (just slightly higher) than the overall market, which is uncharacteristic of a high-growth consumer brand. For investors with a long-term perspective, Lululemon’s powerful brand equity and consistent execution make it an attractive pick.

If you’re looking for more great opportunities, here is a list of our top stock picks for previous 12 months.